Veracyte signs definitive agreement to acquire HalioDx for up to €113M in stock

VERACYTE, INC.

Entered into Securities Purchase and Contribution Agreement on July 13, 2021.
Consideration includes up to €113M in Veracyte common stock, with option to substitute cash.
Closing subject to customary conditions, including French foreign investment authorization.
Stock to be issued in private placement exempt from registration under Section 4(a)(2) and/or Regulation S.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.